Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P48651
UPID:
PTSS1_HUMAN
Alternative names:
Serine-exchange enzyme I
Alternative UPACC:
P48651; B4DE85; E5RFC5; Q9BUQ5
Background:
Phosphatidylserine synthase 1, also known as Serine-exchange enzyme I, plays a crucial role in cellular membrane composition and function. It catalyzes the base-exchange reaction, primarily converting phosphatidylcholine to phosphatidylserine, a key process in membrane dynamics and signaling pathways.
Therapeutic significance:
The protein's involvement in Lenz-Majewski hyperostotic dwarfism, a syndrome marked by intellectual disability and skeletal anomalies, underscores its potential as a therapeutic target. Understanding the role of Phosphatidylserine synthase 1 could open doors to potential therapeutic strategies.